90% Clients recommended this clinic
Medical procedures 
Lutetium-177 PSMA Prostate Radioligand Therapy Program The Lutetium-177 (Lu-177) PSMA Prostate Radioligand Therapy Program is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program provides a structured and carefully monitored therapeutic pathway designed for precise tumor targeting and controlled systemic treatment. Prior to therapy, previously performed PSMA PET/CT imaging is reviewed to confirm adequate PSMA receptor expression and to evaluate disease distribution. Based on this molecular imaging assessment, treatment eligibility and final therapy planning are determined individually. The therapy utilizes Lutetium-177, a beta-emitting radioisotope linked to a PSMA-targeting molecule that selectively binds to prostate cancer cells. After binding and internalization, Lutetium-177 delivers targeted radiation to tumor tissue, leading to DNA damage and controlled destruction of cancer cells while minimizing exposure to surrounding healthy tissues. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Due to the moderate tissue penetration range of beta radiation, Lu-177 PSMA therapy enables effective treatment of metastatic lesions while maintaining a favorable safety profile. This therapy is widely used for advanced prostate cancer patients requiring systemic targeted treatment. The program is conducted under the medical supervision of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, with more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. Nuclear medicine consultation Comprehensive laboratory testing to assess kidney, liver, and hematologic function MAG-3 renal scintigraphy Administration of Lutetium-177 PSMA therapy Post-treatment imaging Coordinated follow-up by a nuclear medicine specialist, including verification of residual radioactivity to ensure flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.
Accommodation 
Transport 
24/7 Bookimed assistance 
Bookimed is an international medical tourism platform founded in 2014. We are made of people and for people — and that’s our core value. We cooperate with simply the best doctors & clinics and work hard every day to make people healthier and happier. Over 800,000 patients used the platform so far. Additionally to our primary activities, we collaborate with charity projects and create supportive communities. Our main office is in Kyiv, Ukraine, still, we’re online 24/7 wherever you are.
The information provided on the website is not a guide to action and should not be construed as medical advice or treatment recommendation, nor should it be considered a substitute for a visit to a doctor.
